tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Clover’s RSV Vaccine Shows Promise in Phase I

Clover’s RSV Vaccine Shows Promise in Phase I

Clover Biopharmaceuticals Ltd. (HK:2197) has released an update.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Clover Biopharmaceuticals Ltd. has announced positive preliminary results from their Phase I trial for their bivalent RSV vaccine candidate, SCB-1019, showing promising immunogenicity and safety in older adults. The vaccine, leveraging the company’s Trimer-Tag technology, demonstrated high neutralizing antibody titers and a favorable safety profile, with no serious adverse events reported. These results suggest SCB-1019 may offer a competitive edge in the global vaccine market, with full Phase I data expected by the end of 2024.

For further insights into HK:2197 stock, check out TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1